Melflufen for Elderly Patients With Relapsed Myeloma
Melflufen for Elderly Myeloma Patients in Second or Subsequent Relapse
This is a pilot study aimed to evaluate the efficacy and tolerability of melflufen plus dexamethasone in elderly patients at second relapse.
Thirty elderly patients at second or subsequent relapse.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Vittorio Montefusco, MD
- Email: vittorio.montefusco@asst-santipaolocarlo.it
Study Contact Backup
- Name: Mario Boccadoro, MD
- Phone Number: +39 011 0240704
- Email: mario.boccadoro@unito.it
Study Locations
-
-
-
Ancona, Italy
- A.O.U. delle Marche
-
Legnano, Italy
- Ospedale Nuovo di Legnano
-
Milano, Italy
- Ospedale Niguarda
-
Milano, Italy
- Ospedale S. Carlo Borromeo
-
Palermo, Italy
- Policlinico Giaccone Divisione Ematologia e Centro Trapianti di Midollo
-
Parma, Italy
- A.O.U. di Parma
-
Pisa, Italy
- A.O.U. Pisana
-
San Giovanni Rotondo, Italy
- I.R.C.C.S. Ospedale Casa Sollievo della Sofferenza
-
Torino, Italy
- A.O.U. Città della Salute e della Scienza di Torino-SSD Clinical trials
-
Udine, Italy
- Ospedale S. Maria della Misericordia di Udine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients affected by MM progressed or relapsed after 2 or more previous lines of therapy.
- Patient is, in the investigator's opinion, willing and able to comply with the study visits and procedures required per protocol.
- Patient has provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any study-specific activities or procedures. Subject does not have kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent and patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements.
- Life expectancy ≥ 3 months
- Previous exposure to, at least, one drug of all the following categories: an anti-CD38 MoAbs, an IMiD, and a proteasome inhibitor.
- Age ≥ 70 and ≤ 85 years.
- ECOG performance status ≤2.
- Subject must have serum monoclonal paraprotein (M-protein) level ≥0.5 g/dL or urine M-protein level ≥200 mg/24 hours, or serum immunoglobulin involved free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio.
- LVEF ≥40% as determined by a MUGA scan or ECHO.
- Adequate hepatic function characterized by the following:
oTotal bilirubin ≤1.5 x ULN. oAST ≤2.5 x ULN oALT ≤2.5 x ULN.
- Estimated creatinine clearance ≥30 mL/min (according to the Cockcroft Gault formula, by 24-hour urine collection for creatinine clearance, or per the local institutional standard method).
Adequate BM function characterized by the following:
- Absolute neutrophil count ≥1.0 × 109/L (use of granulocyte-colony stimulating factors is permitted if completed at least 7 days prior to planned start of dosing).
- Platelet count ≥50 × 109/L (transfusion support is not permitted).
- Hemoglobin ≥8 g/dL (transfusion support is permitted).
- Non-vasectomized male patients agree to practice appropriate methods of birth control
Exclusion Criteria:
- Previous exposure to chemotherapy (i.e. melphalan, high-dose melphalan and/or cyclophosphamide) with the exception of patients who have received an autologous stem cell transplantion with a progression free survival of at least 36 month.
- Plasma cell leukemia.
- Systemic amyloid light chain amyloidosis.
- POEMS Syndrome.
- Central Nervous System (CNS) disease localization.
- Subject with another tumor, not including MM, that required ongoing treatment or therapy completed less than 6 months before eligibility confirmation, and considered at substantial risk of relapse in the following 12 months.
- Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection. Active infections must be resolved at least 14 days prior to eligibility confirmation.
- Subject has any concurrent medical condition or disease (e.g. active systemic infection) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.
Subject has clinically significant cardiac disease, including:
- Myocardial infarction within 6 months before trial eligibility
- Uncontrolled disease/condition related to or affecting cardiac function (e.g. unstable angina, congestive heart failure, New York Heart Association Class III-IV)
- Clinically significant ECG abnormalities.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Melflufen and Dexamethasone
|
Pepaxti 20 mg powder for concentrate for solution for infusion
SOLDESAM 8 mg/2 ml solution for injection SOLDESAM 0.2% oral drops, solution
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Response Rate
Time Frame: approximately 6 months after the enrolled of the last participant and an updated analysis will be conducted at approximately 8 to 12 months.
|
rate of participants who achieve a PR or better (PR+VGPR+CR+sCR) according to IMWG response criteria during the treatment.
|
approximately 6 months after the enrolled of the last participant and an updated analysis will be conducted at approximately 8 to 12 months.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
DURATION OF RESPONSE
Time Frame: after 2.5 years
|
the time from the date of first documented response (≥PR) to the date of first confirmed PD.
|
after 2.5 years
|
|
PROGRESSION-FREE SURVIVAL
Time Frame: after 6 months
|
the time from the date of 1st dose of study drug to the date of first confirmed PD or death due to any cause, whichever occurs first.
|
after 6 months
|
|
TIME TO PROGRESSION
Time Frame: after 2.5 years
|
the time from the date of 1st dose of study drug to the date of first documented PD
|
after 2.5 years
|
|
PROGRESSION-FREE SURVIVAL 2
Time Frame: after 2.5 years
|
the time from the date of 1st dose of study drug to the date of event, which is defined as death from any cause or PD that starts after the next line of therapy, whichever occurs first.
|
after 2.5 years
|
|
OVERALL SURVIVAL
Time Frame: after 2.5 years
|
the time from the date of 1st dose of study drug to the date of death.
|
after 2.5 years
|
|
TIME TO RESPONSE
Time Frame: after 2.5 years
|
the time from the date of 1st dose of study drug to the first documented response (≥PR).
|
after 2.5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Neoplasms
- Disease Attributes
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Recurrence
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Antineoplastic Agents
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antiemetics
- Autonomic Agents
- Peripheral Nervous System Agents
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
Other Study ID Numbers
- MELISSA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.